Vol 5, No 4 (2016)
Review article
Published online: 2016-11-03
Insulin therapy and lipoproteins in patients with type 1 diabetes
DOI: 10.5603/DK.2016.0019
Clin Diabetol 2016;5(4):111-116.
Abstract
Knowledge on HDL cholesterol has been extended, however, there are still unknown facts, especially concerning HDL cholesterol, type 1 diabetes mellitus and insulin therapy. It is known that HDL is responsible for the transport of cholesterol to the liver. It is called the “good cholesterol” due to its advantageous properties. HDL cholesterol reduces cardiovascular risk by its anti-inflammatory, antioxidant, profibrinolytic and antithrombotic effects. The influence of HDL on the incidence of chronic complications of type 1 diabetes has not been yet fully understood. The researchers observed an increase in HDL cholesterol level after initiation of insulin therapy. Significant is the fact that insulin affects lipoprotein metabolism in type 1 diabetes, as it is the treatment of choice in this group of patients.
Keywords: lipoproteinstype 1 diabetesHDL cholesterolinsulin therapychronic diabetic complications
References
- Saboo B. Key elements of successful intensive therapy in patients with type 1 diabetes. Indian J Endocrinol Metab. 2015; 19(Suppl 1): S44–S46.
- Albers JW, Herman WH, Pop-Busui R, et al. Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010; 33(5): 1090–1096.
- Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Kliniczna. 2016; 5(suppl A): A8.
- Murray RK, Granner DK, Rodwell VW. Biochemia Harpera. PZWL, Warszawa 2010: 267.
- Barter P. Abnormal Laboratory Results: HDL cholesterol testing: implications for clinical management. Australian Prescriber. 1994; 17(4): 99–102.
- Kuliszkiewicz-Janus M, Mohamed AS, Abod N. [The biology of HDL lipoprotein and its antisclerotic activity]. Postepy Hig Med Dosw (Online). 2006; 60: 307–315.
- Rosenson RS, Brewer HB, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011; 57(3): 392–410.
- Schmitt JK, Harriman K, Poole JR. Modification of therapy from insulin to chlorpropamide decreases HDL cholesterol in patients with non-insulin-dependent diabetes mellitus. Diabetes Care. 1987; 10(6): 692–696.
- Sinha A, Formica C, Tsalamandris C, et al. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes. Diabet Med. 1996; 13(1): 40–46.
- Wilson DP, Fesmire JD, Endres RK, et al. Increased levels of HDL-cholesterol and apolipoprotein A-I after intensified insulin therapy for diabetes. South Med J. 1985; 78(6): 636–638.
- Guy J, Ogden L, Wadwa RP, et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care. 2009; 32(3): 416–420.
- Araszkiewicz A, Zozulinska-Ziolkiewicz D, Trepinska M, et al. Knowledge after five-day teaching program in intensive insulin therapy performed at the onset of type 1 diabetes influence the development of late diabetic complications. Diabetes Res Clin Pract. 2008; 81(1): 61–67.
- Chillarón JJ, Flores-Le-Roux JA, Goday A, et al. [Metabolic syndrome and type-1 diabetes mellitus: prevalence and associated factors]. Rev Esp Cardiol. 2010; 63(4): 423–429.
- Rogowicz-Frontczak A, Araszkiewicz A, Pilacinski S, et al. Carotid intima-media thickness and arterial stiffness in type 1 diabetic patients with and without microangiopathy. Arch Med Sci. 2012; 8(3): 484–490.
- Witte DR, Tesfaye S, Chaturvedi N, et al. EURODIAB Prospective Complications Study Group. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005; 48(1): 164–171.
- Sun JK, Keenan HA, Cavallerano JD, et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study. Diabetes Care. 2011; 34(4): 968–974.
- Soedamah-Muthu SS, Vergouwe Y, Costacou T, et al. Predicting major outcomes in type 1 diabetes: a model development and validation study. Diabetologia. 2014; 57(11): 2304–2314.
- Molitch ME, Rupp D, Carnethon M. Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes. Diabetes Care. 2006; 29(1): 78–82.
- Wierusz-Wysocka B, Zozulinska DA, Araszkiewicz A, et al. Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes: Response to Molitch et al. Diabetes Care. 2006; 29(5): 1176–1177.
- Lyons T, Jenkins A, Zheng D, et al. Diabetic Retinopathy and Serum Lipoprotein Subclasses in the DCCT/EDIC Cohort. Investigative Opthalmology & Visual Science. 2004; 45(3): 910–918.
- Tolonen N, Hietala K, Forsblom C, et al. FinnDiane Study Group. Associations and interactions between lipid profiles, retinopathy and nephropathy in patients with type 1 diabetes: the FinnDiane Study. J Intern Med. 2013; 274(5): 469–479.
- Medina-Bravo P, Medina-Urrutia A, Juárez-Rojas JG, et al. Glycemic control and high-density lipoprotein characteristics in adolescents with type 1 diabetes. Pediatr Diabetes. 2013; 14(6): 399–406.
- Kalogerakis G, Baker AM, Christov S, et al. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease. Clin Sci (Lond). 2005; 108(6): 497–506.